Skip Navigation LinksHome > June 2014 - Volume 46 - Issue 4 > Molecular biomarkers for predicting outcomes in urothelial c...
Pathology:
doi: 10.1097/PAT.0000000000000110
Reviews

Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder

Sapre, Nikhil; Herle, Praduymna; Anderson, Paul D.; Corcoran, Niall M.; Hovens, Christopher M.

Collapse Box

Abstract

Summary

Molecular biomarkers are used routinely in the clinical management of several tumours such as prostate, colon, ovarian and pancreatic cancer but management decisions in bladder cancer remain dependent on clinical and pathological criteria, which are limited in their ability to predict outcomes. Molecular markers are urgently needed in detection, surveillance and prognostication of bladder cancer as well as to predict treatment response to intravesical and systemic therapies. Advances in cancer genomics and platforms for biomarker profiling have led to a plethora of biomarkers, which must now be rigorously validated in the clinical setting. Pre-clinical and clinical studies exploring the role of emerging targeted therapies to risk stratify and reduce cancer progression are also needed.

© 2014 Royal College of pathologists of Australasia

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.